Abstract

IntroductionWorldwide, the incidence and mortality of lung cancer are at the highest levels, and the most lesions are located in the lung periphery. Despite extensive screening and diagnosis, the pathologic types of peripheral pulmonary lesions (PPLs) are difficult to diagnose by noninvasive examination. This study aimed to identify a novel index—time difference of arrival (TDOA)—to discriminate between benign inflammation and malignant PPLs.MethodsUsing contrast-enhanced ultrasound (CEUS), we retrospectively analyzed 96 patients with PPLs who had undergone biopsy to confirm the pathologic types. All data were collected from Dazhou Central Hospital between December 2012 and July 2019. The parameters of CEUS were analyzed by two assistant chief physicians of ultrasound diagnosis. Area under the receiver operating characteristic curve analysis, sensitivity, specificity, positive predictive value, and negative predictive value were calculated to assess the diagnostic ability of different indices.ResultsWe found that the TDOA significantly distinguished benign inflammation from malignant lesions. The TDOA was markedly increased in patients with malignant lesions than benign inflammation lesions (P < 0.001). Compared with conventional time-intensity curve (TIC) indices, TDOA showed high diagnostic accuracy (area under the curve = 0.894). Moreover, conventional diagnostic indices did not affect the diagnostic performance of TDOA by adjusting the receiver operating characteristic curve.ConclusionTDOA is feasible for the diagnosis of benign inflammation and malignant PPLs.

Highlights

  • Worldwide, the incidence and mortality of lung cancer are at the highest levels, and the most lesions are located in the lung periphery

  • The time difference of arrival (TDOA) was markedly increased in patients with malignant lesions than benign inflammation lesions (P < 0.001)

  • We found that the perfusion method, time to peak intensity (TTP), and peak intensity (PI) produced by contrast-enhanced ultrasound (CEUS) showed no difference between the benign inflammation and malignant lesions groups (P > 0.05) (Table 2)

Read more

Summary

Introduction

The incidence and mortality of lung cancer are at the highest levels, and the most lesions are located in the lung periphery. The 5-year survival rate of lung cancer is about 70%–90% in the early stage [3,4,5], but approximately 75% patients are first diagnosed only in an advanced stage [6] Common clinical methods such as dynamic contrastenhanced magnetic resonance imaging [7], contrast-enhanced computed tomography [8, 9], low-dose computed tomography [10], and bronchoscopy [11] are used to diagnose the lung lesions. These methods have obvious diagnostic shortcomings, such as exposure to heavy dose of radiation [12], high cost [13, 14], and high false positive rates [15, 16]. It is essential to improve the current screening and diagnostic ability

Objectives
Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call